Quantitative 177Lu SPECT/CT imaging for personalized dosimetry using a ring-shaped CZT-based camera

Quantitative 177Lu SPECT/CT imaging for personalized dosimetry using a ring-shaped CZT-based camera

Abstract Background Dosimetry after radiopharmaceutical therapy with 177Lu (177Lu-RPT) relies on quantitative SPECT/CT imaging, for which suitable reconstruction protocols are required. In this study, we characterized for the first time the quantitative performance of a ring-shaped CZT-based camera...

Full description

Bibliographic Details
Main Authors:	Rachele Danieli, Martina Stella, Julian Leube, Johannes Tran-Gia, Clementine Marin, Carlos F. Uribe, Bruno Vanderlinden, Nick Reynaert, Patrick Flamen, Hugo Levillain
Format:	Article
Language:	English
Published:	SpringerOpen 2023-10-01
Series:	EJNMMI Physics
Subjects:	SPECT/CT Calibration Image reconstruction Block sequential regularized expectation maximization (BSREM) Quantitative Lu-177 SPECT Dosimetry
Online Access:	https://doi.org/10.1186/s40658-023-00586-z

Similar Items

Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
by: Sandra Resch, et al.
Published: (2023-02-01)

Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
by: Alessandro Desy, et al.
Published: (2020-05-01)

Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points
by: Gefei Chen, et al.
Published: (2023-11-01)

Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for $$^{177}$$ 177 Lu-DOTATATE therapy
by: Laure Vergnaud, et al.
Published: (2022-05-01)

Effect of kilovoltage and quality reference mAs on CT-based attenuation correction in 177Lu SPECT/CT imaging: a phantom study
by: Maikol Salas-Ramirez, et al.
Published: (2024-02-01)

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
by: Sejin Ha, et al.
Published: (2024-02-01)

Performance study of a 360° CZT camera for monitoring 177Lu-PSMA treatment
by: Laure Vergnaud, et al.
Published: (2023-09-01)

Accuracy of two dosimetry software programs for 177Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
by: Keamogetswe Ramonaheng, et al.
Published: (2022-07-01)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)

Impact of different models based on blood samples and images for bone marrow dosimetry after 177Lu-labeled somatostatin-receptor therapy
by: Delphine Vallot, et al.
Published: (2024-04-01)

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
by: Anna Sundlöv, et al.
Published: (2018-07-01)

Comparison of a 3D CZT and conventional SPECT/CT system for quantitative Lu-177 SPECT imaging
by: Victor Nuttens, et al.
Published: (2024-03-01)

Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
by: Catherine Meyer, et al.
Published: (2023-12-01)

Anatomy-based correction of kidney PVE on $$^{177}\text{Lu}$$ 177 Lu SPECT images
by: Julien Salvadori, et al.
Published: (2024-02-01)

A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project
by: Johannes Tran-Gia, et al.
Published: (2021-07-01)

The Accuracy of TIAC Calculated Using SPECT/CT Imaging Data at 36- and 100-Hours Post Injection and Prior Information in 177Lu-DOTATATE
by: Rizka Mutik Siyami, et al.
Published: (2023-11-01)

Analysis of a deep learning-based method for generation of SPECT projections based on a large Monte Carlo simulated dataset
by: Julian Leube, et al.
Published: (2022-07-01)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
by: Peter Frøhlich Staanum, et al.
Published: (2021-11-01)

Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives
by: Rahaf Alsadi, et al.
Published: (2022-07-01)

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01)

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
by: Keamogetswe Ramonaheng, et al.
Published: (2024-03-01)

Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-12-01)

Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm
by: Peter Frøhlich Staanum
Published: (2023-06-01)

The Challenge of Single-Photon Emission Computed Tomography Image Segmentation in the Internal Dosimetry of <sup>177</sup>Lu Molecular Therapies
by: Joanna Gawel, et al.
Published: (2024-01-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
by: Dagmar Grob, et al.
Published: (2024-04-01)

Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
by: Hongmei Li, et al.
Published: (2024-03-01)

Towards accurate 177Lu SPECT activity quantification and standardization using lesion-to-background voxel ratio
by: Stanislav Raskin, et al.
Published: (2023-01-01)

Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
by: Siju C. George, et al.
Published: (2023-07-01)

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
by: Alexandre Chicheportiche, et al.
Published: (2020-01-01)

Corrigendum: Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
by: Siju C. George, et al.
Published: (2024-04-01)

Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
by: Mattias Sandström, et al.
Published: (2020-12-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Extravasation of [177Lu]Lu-DOTATOC: case report and discussion
by: Anne Kirstine Arveschoug, et al.
Published: (2020-06-01)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
by: Frederik A. Verburg, et al.
Published: (2023-11-01)

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
by: Andreas Rinscheid, et al.
Published: (2020-06-01)

A single-institution experience with 177Lu RPT workflow improvements and qualifying the SPECT/CT imaging for dosimetry
by: Siju C. George, et al.
Published: (2024-02-01)

Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies
by: Lachlan McIntosh, et al.
Published: (2024-02-01)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
by: Michela Del Prete, et al.
Published: (2018-10-01)